Lilly links COVID-19 antibody to reduced hospitalization rate

Eli Lilly has linked its anti-SARS-CoV-2 antibody to a lower rate of hospitalization in patients recently diagnosed with mild to moderate cases of COVID-19.

 In June, the company began a trial delivering either placebo or an antibody, called LY-CoV555, to 452 patients. These were patients with mild or moderate symptoms who had tested positive for SARS-CoV-2 within the past 3 days and had not been hospitalized.

1.7% of the patients who received the drug ended up being hospitalized and 6% of the placebo patients ended up in the hospital. This showed a 72% reduction in the risk of hospitalization. However, among the 3 different doses in the trial, the lowest and highest dose did not show the effect.